Clinical Trial Update: The Willow LTE Study With M5049 in Participants With SCLE, DLE and/or SLE (WILLOW LTE) [Phase 2]

View source ↗

Summary

Merck's Phase 2 WILLOW LTE trial evaluating M5049 for systemic lupus erythematosus (including cutaneous lupus subtypes) is currently active but not recruiting. …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Lupus Erythematosus

Drugs mentioned

• M5049

Snippet

Sponsor: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | Conditions: Systemic Lupus Erythematosus | Phase 2 | Status: ACTIVE_NOT_RECRUITING